天才1207的个人主页 - 老虎社区

天才1207

暂无个人介绍

IP属地：天津

0关注

0粉丝

0主题

0勋章

2025-10-03

说说你对这篇新闻的看法...

抱歉，原内容已删除

05-05

忽然砸单是发生了什么吗？

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4213755732132142","uuid":"4213755732132142","gmtCreate":1750652541024,"gmtModify":1750693326163,"name":"天才1207","pinyin":"tc1207tiancai1207","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"天津","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":560815283053192,"gmtCreate":1777949490422,"gmtModify":1777955266667,"author":{"id":"4213755732132142","authorId":"4213755732132142","name":"天才1207","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4213755732132142","authorIdStr":"4213755732132142"},"themes":[],"title":"","htmlText":"忽然砸单是发生了什么吗？","listText":"忽然砸单是发生了什么吗？","text":"忽然砸单是发生了什么吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/560815283053192","isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":485164428165568,"gmtCreate":1759477442016,"gmtModify":1759478277605,"author":{"id":"4213755732132142","authorId":"4213755732132142","name":"天才1207","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4213755732132142","authorIdStr":"4213755732132142"},"themes":[],"title":"","htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/485164428165568","repostId":"2572572094","repostType":2,"repost":{"id":"2572572094","kind":"news","pubTimestamp":1759476661,"share":"https://www.laohu8.com/m/news/2572572094?lang=zh_CN&edition=full","pubTime":"2025-10-03 15:31","market":"hk","language":"zh","title":"港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2572572094","media":"智通财经","summary":"智通财经APP获悉，宜明昂科-B(01541)再涨超6%，截至发稿，涨6.69%，报15.15港元，成交额4567.05万港元。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","content":"<html><head></head><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/01541\">宜明昂科-B</a>(01541)再涨超8%、五日累涨38%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/1a163769f260eb9f5d2ff68b91dac308\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p>消息面上，宜明<a href=\"https://laohu8.com/S/02216\">昂科</a>昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。</p><p>此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-03 15:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1352101.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1352101.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/86700e5998d8a25a4fe570ae31b092f1","relate_stocks":{"BK1161":"生物科技","LU1223082196.USD":"施罗德环球黄金A Acc","01541":"宜明昂科-B","BK4017":"黄金","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","BK4134":"信息科技咨询与其它服务","BK4614":"Manus概念股"},"source_url":"http://www.zhitongcaijing.com/content/detail/1352101.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2572572094","content_text":"智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","news_type":1,"symbols_score_info":{"01541":1.1}},"isVote":1,"tweetType":1,"viewCount":1567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":485164428165568,"gmtCreate":1759477442016,"gmtModify":1759478277605,"author":{"id":"4213755732132142","authorId":"4213755732132142","name":"天才1207","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4213755732132142","idStr":"4213755732132142"},"themes":[],"title":"","htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/485164428165568","repostId":"2572572094","repostType":2,"isVote":1,"tweetType":1,"viewCount":1567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":560815283053192,"gmtCreate":1777949490422,"gmtModify":1777955266667,"author":{"id":"4213755732132142","authorId":"4213755732132142","name":"天才1207","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4213755732132142","idStr":"4213755732132142"},"themes":[],"title":"","htmlText":"忽然砸单是发生了什么吗？","listText":"忽然砸单是发生了什么吗？","text":"忽然砸单是发生了什么吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/560815283053192","isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}